Stockscreener 앱 받기
6.03
0.99%
-0.06
시간 외 거래:
6.06
0.03
+0.50%
전일 마감가:
$6.09
열려 있는:
$6
하루 거래량:
19.49M
Relative Volume:
2.17
시가총액:
$2.36B
수익:
$64.60M
순이익/손실:
$-377.75M
주가수익비율:
-4.3696
EPS:
-1.38
순현금흐름:
$-335.64M
1주 성능:
-13.24%
1개월 성능:
-0.17%
6개월 성능:
-34.10%
1년 성능:
-36.26%
1일 변동 폭
$5.93
$6.20
1주일 범위
$5.93
$7.85
52주 변동 폭
$5.60
$15.74
리커젼 파마 Stock (RXRX) Company Profile
명칭
Recursion Pharmaceuticals Inc
전화
(385) 269-0203
주소
41S RIO GRANDE STREET, SALT LAKE CITY
RXRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
6.03 | 2.36B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
리커젼 파마 Stock (RXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-05-22 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 개시 | Needham | Buy |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-04 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 개시 | Berenberg | Buy |
| 2021-05-11 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Goldman | Neutral |
| 2021-05-11 | 개시 | JP Morgan | Neutral |
| 2021-05-11 | 개시 | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 개시 | SVB Leerink | Outperform |
모두보기
리커젼 파마 주식(RXRX)의 최신 뉴스
Is Recursion Pharmaceuticals Stock a Millionaire Maker? - Yahoo! Voices
When (RXRX) Moves Investors should Listen - Stock Traders Daily
1 Artificial Intelligence (AI) Stock That Could Soar in 2025 - Yahoo Finance
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules - The Manila Times
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - AOL
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 0.7%Here's Why - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.6% HigherHere's Why - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap UpTime to Buy? - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 3.4%Time to Sell? - MarketBeat
Recursion Pharmaceuticals registers shares for Tempus Labs - Investing.com India
Recursion Pharmaceuticals registers shares for Tempus Labs By Investing.com - Investing.com UK
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 5.5%Here's What Happened - MarketBeat
State Street Corp Raises Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.8%Here's What Happened - MarketBeat
Layoff Tracker: Editas Will Cut 60% of Staff - BioSpace
Recursion Pharmaceuticals (NASDAQ:RXRX) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo Finance
Jim Cramer Says He Was Wrong on NVIDIA Holding Recursion Pharmaceuticals (RXRX) - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.4% HigherShould You Buy? - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3%What's Next? - MarketBeat
Interesting RXRX Put And Call Options For January 2025 - Nasdaq
Recursion Pharmaceuticals’ (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials - Insider Monkey
Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform - Seeking Alpha
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 0.7%Here's Why - MarketBeat
Why Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short Sellers - Insider Monkey
Recursion Pharmaceuticals (NASDAQ:RXRX) Receives Buy Rating from Needham & Company LLC - MarketBeat
10 AI News Investors Probably Missed - Insider Monkey
(RXRX) Trading Report - Stock Traders Daily
10 Worst ARK Stocks To Buy According to Short Sellers - Insider Monkey
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.2%Should You Sell? - MarketBeat
Unpacking the Latest Options Trading Trends in Recursion Pharmaceuticals - Benzinga
What's Going On With Recursion Pharmaceuticals Stock?Recursion Pharmaceuticals (NASDAQ:RXRX) - Benzinga
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 21.5% HigherShould You Buy? - MarketBeat
Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245 (NASDAQ:RXRX) - Seeking Alpha
Charles Schwab Investment Management Inc. Has $12.79 Million Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Fmr LLC Buys 170,810 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by Benjamin Edwards Inc. - MarketBeat
Recursion Pharmaceuticals CEO sells $285,600 in stock By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals CEO sells $285,600 in stock - Investing.com India
RXRX Stock Earnings: Recursion Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.7%Time to Buy? - MarketBeat
Stock Traders Purchase High Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 6.9%Should You Sell? - MarketBeat
The Future of Medicine: How AI Is Transforming Healthcare and Stock Markets - Baystreet.ca
리커젼 파마 (RXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):